Medicine & Life Sciences
pembrolizumab
100%
Drug Therapy
76%
Trastuzumab
75%
Small Cell Lung Carcinoma
70%
Placebos
58%
Stomach Neoplasms
54%
Phase IV Clinical Trials
54%
atezolizumab
50%
pertuzumab
49%
Afatinib
48%
Vinorelbine
42%
Breast Neoplasms
40%
Safety
40%
Erlotinib Hydrochloride
40%
Phase III Clinical Trials
38%
Organized Financing
37%
Docetaxel
35%
Adenocarcinoma of Lung
33%
ErbB Receptors
32%
Non-Small Cell Lung Carcinoma
32%
Progression-Free Survival
32%
Albumins
27%
Etoposide
26%
Ligands
26%
Breast
24%
Randomized Controlled Trials
21%
Therapeutics
20%
Mutation
19%
Hematopoietic Stem Cells
18%
Neutropenia
17%
Expert Testimony
16%
Mortality
15%
Survival
14%
Neoplasms
14%
Esophagogastric Junction
10%
Population
9%
Febrile Neutropenia
9%
Erythrocyte Transfusion
9%
4-nitrophenyl chloromethyl(phenyl)phosphinate
9%
Intention
9%
Medicine
8%
Clinical Trials
7%
Platinum
7%
Random Allocation
7%
Latvia
6%
Quality of Life
6%
Ilex
6%
Medical Writing
6%
Carboplatin
5%
Hospitalization
5%